Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Pazdur Tapped For New Oncology Office Director

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncology division head Pazdur is selected to lead FDA’s new Office of Oncology Drug Products following national search. Pazdur will begin assuming duties of the office May 1; the office will officially launch in July as part of a broader Office of New Drugs reorganization.
Advertisement

Related Content

FDA Gastroenterology Drugs Division Headed By Harvey; Phase-Out Of ODE V Complete
FDA Gastroenterology Drugs Division Headed By Harvey; Phase-Out Of ODE V Complete
HHS Secretary Leavitt Opens FDA Science Forum April 27
HHS Secretary Leavitt Opens FDA Science Forum April 27
FDA Reorganization Of New Drug Office Would Split Neuropharmaceutical Division
FDA Will Conduct "National Search" For Head Of Oncology Office
FDA Will Conduct "National Search" For Head Of Oncology Office
Chemo-Preventative Agents Will Move To New Cancer Office In Fall

Topics

Advertisement
UsernamePublicRestriction

Register

PS062059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel